Skip to main content
SpringerLink
Log in

Hashimoto’s Encephalopathy

Epidemiology,Pathogenesis and Management

  • Therapy In Practice
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Hashimoto’s encephalopathy is a term used to describe an encephalopathy of presumed autoimmune origin characterised by high titres of antithyroid peroxidase antibodies. In a similar fashion to autoimmune thyroid disease, Hashimoto’s encephalopathy is more common in women than in men. It has been reported in paediatric, adult and elderly populations throughout the world. The clinical presentation may involve a relapsing and remitting course and include seizures, stroke-like episodes, cognitive decline, neuropsychiatric symptoms and myoclonus. Thyroid function is usually clinically and biochemically normal.

Hashimoto’s encephalopathy appears to be a rare disorder, but, as it is responsive to treatment with corticosteroids, it must be considered in cases of ‘investigation negative encephalopathies’. Diagnosis is made in the first instance by excluding other toxic, metabolic and infectious causes of encephalopathy with neuroimaging and CSF examination. Neuroimaging findings are often not helpful in clarifying the diagnosis. Common differential diagnoses when these conditions are excluded are Creutzfeldt-Jakob disease, rapidly progressive dementias, and paraneoplastic and nonparaneoplastic limbic encephalitis. In the context of the typical clinical picture, high titres of antithyroid antibodies, in particular antithyroid peroxidase antibodies, are diagnostic. These antibodies, however, can be detected in elevated titres in the healthy general population. Treatment with corticosteroids is almost always successful, although relapse may occur if this treatment is ceased abruptly. Other forms of immunomodulation, such as intravenous immune-globulin and plasma exchange, may also be effective.

Despite the link to autoimmune thyroid disease, the aetiology of Hashimoto’s encephalopathy is unknown. It is likely that antithyroid antibodies are not pathogenic, but titres can be a marker of treatment response. Pathological findings can suggest an inflammatory process, but features of a severe vasculitis are often absent. The links between the clinical pictures, thyroid disease, auto-antibody pattern and brain pathology await further clarification through research. It may be that Hashimoto’s encephalopathy will be subsumed into a group of nonvasculitic autoimmune inflammatory meningoencephalopathies. This group may include disorders such as limbic encephalitis associated with voltage-gated potassium channel antibodies. Some authors have suggested abandoning any link to Hashimoto and renaming the condition ‘steroid responsive encephalopathy associated with autoimmune thyroiditis’ to better reflect current, if limited, understanding of this condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Brain L, Jellinek EH, Ball K. Hashimoto’s disease and encephalopathy. Lancet 1966 Sep 3; 2(7462): 512–4

    Article  PubMed  CAS  Google Scholar 

  2. Ferracci F, Bertiato G, Moretto G. Hashimoto’s encephalopathy: epidemiologic data and pathogenetic considerations. J Neurol Sci 2004 Feb 15; 217(2): 165–8

    Article  PubMed  Google Scholar 

  3. Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol 2003 Feb; 60(2): 164–71

    Article  PubMed  Google Scholar 

  4. Galluzzi S, Geroldi C, Zanetti O, et al. Hashimoto’s encephalopathy in the elderly: relationship to cognitive impairment. J Geriatr Psychiatry Neurol 2002; 15(3): 175–9

    PubMed  Google Scholar 

  5. Vasconcellos E, Pina-Garza JE, Fakhoury T, et al. Pediatric manifestations of Hashimoto’s encephalopathy. Pediatr Neurol 1999 May; 20(5): 394–8

    Article  PubMed  CAS  Google Scholar 

  6. Chaudhuri A, Behan PO. The clinical spectrum, diagnosis, pathogenesis and treatment of Hashimoto’s encephalopathy (recurrent acute disseminated encephalomyelitis). Curr Med Chem 2003 Oct; 10(19): 1945–53

    Article  PubMed  CAS  Google Scholar 

  7. Byrne OC, Zuberi SM, Madigan CA, et al. Hashimoto’s thyroiditis: a rare but treatable cause of encephalopathy in children. Eur J Paediatr Neurol 2000; 4(6): 279–82

    Article  PubMed  CAS  Google Scholar 

  8. Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006 Feb; 63(2): 197–202

    Article  PubMed  Google Scholar 

  9. Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev 2003 Oct; 24(5): 694–717

    Article  PubMed  CAS  Google Scholar 

  10. Ban Y, Tomer Y. Genetic susceptibility in thyroid autoimmunity. Pediatr Endocrinol Rev 2005 Sep; 3(1): 20–32

    PubMed  Google Scholar 

  11. Fatourechi V. Hashimoto’s encephalopathy: myth or reality? An endocrinologist’s perspective. Best Pract Res Clin Endocrinol Metab 2005 Mar; 19(1): 53–66

    Article  PubMed  CAS  Google Scholar 

  12. McCabe DJ, Burke T, Connolly S, et al. Amnesic syndrome with bilateral mesial temporal lobe involvement in Hashimoto’s encephalopathy. Neurology 2000; 54(3): 737–9

    Article  PubMed  CAS  Google Scholar 

  13. Stone J, Campbell IW, Moran GD, et al. A case of reversible amnesia [letter]. Postgrad Med J 2001 Jan; 77(903): 56

    Article  Google Scholar 

  14. Ferlazzo E, Raffaele M, Mazzu I, et al. Recurrent status epilepticus as the main feature of Hashimoto’s encephalopathy. Epilepsy Behav 2006 Feb; 8(1): 328–30

    Article  PubMed  Google Scholar 

  15. McGinley J, McCabe DJ, Fraser A, et al. Hashimoto’s encephalopathy: an unusual cause of status epilepticus [letter]. Ir ed J 2000 Jun; 93(4): 118

    CAS  Google Scholar 

  16. Arain A, Abou-Khalil B, Moses H. Hashimoto’s encephalopathy: documentation of mesial temporal seizure origin by ictal EEG. Seizure 2001 Sep; 10(6): 438–41

    PubMed  CAS  Google Scholar 

  17. Sawka AM, Fatourechi V, Boeve BF, et al. Rarity of encephalopathy associated with autoimmune thyroiditis: a case series from Mayo Clinic from 1950 to 1996. Thyroid 2002; 12(5): 393–8

    Article  PubMed  Google Scholar 

  18. Kothbauer-Margreiter I, Sturzenegger M, Komor J, et al. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. J Neurol 1996 Aug; 243(8): 585–93

    Article  PubMed  CAS  Google Scholar 

  19. Chaudhuri A, Behan PO. Hashimoto’s encephalopathy: a relapsing form of acute disseminated encephalomyelitis. J Neurol Sci 2005 Aug 15; 235(1–2): 75–6; author reply, 77

    Article  PubMed  Google Scholar 

  20. Erickson JC, Carrasco H, Grimes JB, et al. Palatal tremor and myorhythmia in Hashimoto’s encephalopathy. Neurology 2002 Feb 12; 58(3): 504–5

    Article  PubMed  CAS  Google Scholar 

  21. Taurin G, Golfier V, Pinel JF, et al. Choreic syndrome due to Hashimoto’s encephalopathy. Mov Disord 2002 Sep; 17(5): 1091–2

    Article  PubMed  Google Scholar 

  22. Selim M, Drachman DA. Ataxia associated with Hashimoto’s disease: progressive non-familial adult onset cerebellar degeneration with autoimmune thyroiditis. J Neurol Neurosurg Psychiatry 2001 Jul; 71(1): 81–7

    Article  PubMed  CAS  Google Scholar 

  23. Brusa L, Panella M, Koch G, et al. Hashimoto’s encephalopathy resenting with musical hallucinosis. J Neurol 2003 May; 250(5): 627–8

    Article  PubMed  Google Scholar 

  24. Mahmud FH, Lteif AN, Renaud DL, et al. Steroid-responsive encephalopathy associated with Hashimoto’s thyroiditis in an adolescent with chronic hallucinations and depression: case report and review. Pediatrics 2003 Sep; 112(3 Pt 1): 686–90

    Article  PubMed  Google Scholar 

  25. Mussig K, Bartels M, Gallwitz B, et al. Hashimoto’s encephalopathy presenting with bipolar affective disorder. Bipolar Disord 2005 Jun; 7(3): 292–7

    Article  PubMed  Google Scholar 

  26. Papathanasopoulos P, Mallioris K, Karanasios P, et al. Febrile Hashimoto’s encephalopathy [letter]. J Neurol Neurosurg Psychiatry 2000 Jun; 68(6): 795

    Article  PubMed  CAS  Google Scholar 

  27. Sellal F, Berton C, Andriantseheno M, et al. Hashimoto’s encephalopathy: exacerbations associated with menstrual cycle. Neurology 2002 Nov 26; 59(10): 1633–5

    Article  PubMed  CAS  Google Scholar 

  28. Canton A, de Fabregas O, Tintore M, et al. Encephalopathy associated to autoimmune thyroid disease: a more appropriate term for an underestimated condition? J Neurol Sci 2000; 176(1): 65–9

    Article  PubMed  CAS  Google Scholar 

  29. Chong JY, Rowland LP. What’s in a NAIM? Hashimoto encephalopathy, steroid-responsive encephalopathy associated with autoimmune thyroiditis, or nonvasculitic autoimmune meningoencephalitis? Arch Neurol 2006 Feb; 63(2): 175–6

    Article  PubMed  Google Scholar 

  30. Oide T, Tokuda T, Yazaki M, et al. Anti-neuronal autoantibody in Hashimoto’s encephalopathy: neuropathological, immunohistochemical, and biochemical analysis of two patients. J Neurol Sci 2004 Jan 15; 217(1): 7–12

    Article  PubMed  CAS  Google Scholar 

  31. Heufelder AE, Joba W, Morgenthaler NG. Autoimmunity involving the human sodium/iodide symporter: fact or fiction? Exp Clin Endocrinol Diabetes 2001; 109(1): 35–40

    Article  PubMed  CAS  Google Scholar 

  32. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002 Feb; 87(2): 489–99

    Article  PubMed  CAS  Google Scholar 

  33. Fujii A, Yoneda M, Ito T, et al. Autoantibodies against the amino terminal of alpha-enolase are a useful diagnostic marker of Hashimoto’s encephalopathy. J Neuroimmunol 2005 May; 162(1–2): 130–6

    Article  PubMed  CAS  Google Scholar 

  34. Ochi H, Horiuchi I, Araki N, et al. Proteomic analysis of human brain identifies alpha-enolase as a novel autoantigen in Hashimoto’s encephalopathy. FEBS Lett 2002 Sep 25; 528(1–3): 197–202

    Article  PubMed  CAS  Google Scholar 

  35. Seipelt M, Zerr I, Nau R, et al. Hashimoto’s encephalitis as a differential diagnosis of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 1999; 66(2): 172–6

    Article  PubMed  CAS  Google Scholar 

  36. Peschen-Rosin R, Schabet M, Dichgans J. Manifestation of Hashimoto’s encephalopathy years before onset of thyroid disease. Eur Neurol 1999; 41(2): 79–84

    Article  PubMed  CAS  Google Scholar 

  37. Ferracci F, Moretto G, Candeago RM, et al. Antithyroid antibodies in the CSF: their role in the pathogenesis of Hashimoto’s encephalopathy. Neurology 2003 Feb 25; 60(4): 712–4

    Article  PubMed  CAS  Google Scholar 

  38. Shiga Y, Wakabayashi H, Miyazawa K, et al. 14-3-3 protein levels and isoform patterns in the cerebrospinal fluid of Creutzfeldt-Jakob disease patients in the progressive and terminal stages. J Clin Neurosci 2006 Jul; 13(6): 661–5

    Article  PubMed  CAS  Google Scholar 

  39. Vander T, Hallevy C, Alsaed I, et al. 14-3-3 protein in the CSF of a patient with Hashimoto’s encephalopathy. J Neurol 2004 Oct; 251(10): 1273–4

    Article  PubMed  CAS  Google Scholar 

  40. Schauble B, Castillo PR, Boeve BF, et al. EEG findings in steroid-responsive encephalopathy associated with autoimmune thyroiditis. Clin Neurophysiol 2003 Jan; 114(1): 32–7

    Article  PubMed  Google Scholar 

  41. Song YM, Seo DW, Chang GY. MR findings in Hashimoto encephalopathy. AJNR Am J Neuroradiol 2004 May; 25(5): 07–8

    Google Scholar 

  42. Bohnen NI, Parnell KJ, Harper CM. Reversible MRI findings in a patient with Hashimoto’s encephalopathy. Neurology 1997; 49(1): 246–7

    Article  PubMed  CAS  Google Scholar 

  43. Pozo-Rosich P, Villoslada P, Canton A, et al. Reversible white matter alterations in encephalopathy associated with autoimmune thyroid disease. J Neurol 2002 Aug; 249(8): 1063–5

    Article  PubMed  Google Scholar 

  44. Bertoni M, Falcini M, Sestini S, et al. Encephalopathy associated with Hashimoto’s thyroiditis: an additional case. Eur J Intern Med 2003 Nov; 14(7): 434–7

    Article  PubMed  Google Scholar 

  45. Forchetti CM, Katsamakis G, Garron DC. Autoimmune thyroiditis and a rapidly progressive dementia: global hypoperfusion on SPECT scanning suggests a possible mechanism. Neurology 1997 Aug; 49(2): 623–6

    Article  PubMed  CAS  Google Scholar 

  46. Josephson SA, Papanastassiou AM, Berger MS, et al. The diagnostic utility of brain biopsy procedures in patients with rapidly deteriorating neurological conditions or dementia. J Neurosurg 2007 Jan; 106(1): 72–5

    Article  PubMed  Google Scholar 

  47. Warren JD, Schott JM, Fox NC, et al. Brain biopsy in dementia. Brain 2005 Sep; 128(Pt 9): 2016–25

    Article  PubMed  CAS  Google Scholar 

  48. Jennekens FG, Kater L. The central nervous system in systemic upus erythematosus (Pt 1). Clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002 Jun; 41(6): 605–18

    CAS  Google Scholar 

  49. Bruns A, Meyer O. Neuropsychiatric manifestations of systemic lupus erythematosus. Joint Bone Spine 2006 Dec; 73(6): 639–45

    Article  PubMed  Google Scholar 

  50. Jennekens FG, Kater L. The central nervous system in systemic lupus erythematosus (Pt 2). Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002 Jun; 41(6): 619–30

    CAS  Google Scholar 

  51. Sanna G, Bertolaccini ML, Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus 2003; 12(12): 935–42

    Article  PubMed  CAS  Google Scholar 

  52. Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003 May; 30(5): 985–92

    PubMed  Google Scholar 

  53. Johnson RT, Gibbs Jr CJ. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998 Dec 31; 339(27): 1994–2004

    Article  PubMed  CAS  Google Scholar 

  54. Calabrese L. Primary angiitis of the central nervous system: the penumbra of vasculitis. J Rheumatol 2001; 28(3): 465–6

    PubMed  CAS  Google Scholar 

  55. Imbesi SG. Diffuse cerebral vasculitis with normal results on brain MR imaging. AJR Am J Roentgenol 1999; 173(6): 1494–6

    PubMed  CAS  Google Scholar 

  56. Wasserman BA, Stone JH, Hellmann DB, et al. Reliability of normal findings on MR imaging for excluding the diagnosis of vasculitis of the central nervous system. AJR Am J Roentgenol 2001; 177(2): 455–9

    PubMed  CAS  Google Scholar 

  57. Alrawi A, Trobe JD, Blaivas M, et al. Brain biopsy in primary angiitis of the central nervous system. Neurology 1999 Sep 11; 53(4): 858–60

    Article  PubMed  CAS  Google Scholar 

  58. Caturegli P, Newschaffer C, Olivi A, et al. Autoimmune hypophysitis. Endocr Rev 2005 Aug; 26(5): 599–614

    Article  PubMed  CAS  Google Scholar 

  59. Miyake I, Takeuchi Y, Kuramoto T, et al. Autoimmune hypophysitis treated with intravenous glucocorticoid therapy. Intern Med 2006; 45(21): 1249–52

    Article  PubMed  Google Scholar 

  60. Rivera JA. Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy. Pituitary 2006; 9(1): 35–45

    Article  PubMed  Google Scholar 

  61. Mocellin R, Velakoulis D, Gonzales M, et al. Weight loss, falls, and neuropsychiatric symptoms in a 56 year-old man. Lancet Neurol 2005 Jun; 4(6): 381–8

    Article  PubMed  Google Scholar 

  62. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004 Mar; 127(Pt 3): 701–12

    PubMed  Google Scholar 

  63. Thieben MJ, Lennon VA, Boeve BF, et al. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004 Apr 13; 62(7): 1177–82

    Article  PubMed  CAS  Google Scholar 

  64. Urbach H, Soeder BM, Jeub M, et al. Serial MRI of limbic encephalitis. Neuroradiology 2006 Jun; 48(6): 380–6

    Article  PubMed  Google Scholar 

  65. Sener R. MRI and diffusion MRI in nonparaneoplastic limbic encephalitis. Comput Med Imaging Graph 2002; 26(5): 339–42

    Article  PubMed  CAS  Google Scholar 

  66. Fauser S, Talazko J, Wagner K, et al. FDG-PET and MRI in potassium channel antibody-associated non-paraneoplastic limbic encephalitis: correlation with clinical course and neuropsychology. Acta Neurol Scand 2005 May; 111(5): 338–43

    Article  PubMed  CAS  Google Scholar 

  67. Caviness JN. Myoclonus and neurodegenerative disease: what’s in a name? Parkinsonism Relat Disord 2003 Mar; 9(4): 185–92

    Article  PubMed  Google Scholar 

  68. McKeith IG, Burn DJ, Ballard CG, et al. Dementia with Lewy bodies. Semin Clin Neuropsychiatry 2003; 8(1): 46–57

    Article  PubMed  Google Scholar 

  69. Walker Z, Stevens T. Dementia with Lewy bodies: clinical characteristics and diagnostic criteria. J Geriatr Psychiatry Neurol 2002; 15(4): 188–94

    PubMed  Google Scholar 

  70. Caviness JN, Adler CH, Caselli RJ, et al. Electrophysiology of the myoclonus in dementia with Lewy bodies. Neurology 2003 Feb 11; 60(3): 523–4

    Article  PubMed  CAS  Google Scholar 

  71. Tschampa HJ, Neumann M, Zerr I, et al. Patients with Alzheimer’s disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2001; 71(1): 33–9

    Article  PubMed  CAS  Google Scholar 

  72. Dickson DW, Bergeron C, Chin SS, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61(11): 935–46

    PubMed  CAS  Google Scholar 

  73. Coulier IM, de Vries JJ, Leenders KL. Is FDG-PET a useful tool in clinical practice for diagnosing corticobasal ganglionic degeneration? Mov Disord 2003 Oct; 18(10): 1175–8

    Article  PubMed  Google Scholar 

  74. Velakoulis D, Lloyd JH. The role of SPECT scanning in a neuropsychiatry unit. Aust N Z J Psychiatry 1998 Aug; 32(4): 511–22

    Article  PubMed  CAS  Google Scholar 

  75. Graham NL, Bak TH, Hodges JR. Corticobasal degeneration as a cognitive disorder. Mov Disord 2003 Nov; 18(11): 1224–32

    Article  PubMed  Google Scholar 

  76. Shovman O, Gilburd B, Zandman-Goddard G, et al. Pathogenic role and clinical relevance of antineutrophil cytoplasmic antibodies in vasculitides. Curr Rheumatol Rep 2006 Aug; 8(4): 292–8

    Article  PubMed  CAS  Google Scholar 

  77. Paulus W, Nolte KW. Neuropathology of Hashimoto’s encephalopathy. J Neurol Neurosurg Psychiatry 2003 Jul; 74(7):1009; author reply, 1009

    Article  PubMed  CAS  Google Scholar 

  78. Duffey P, Yee S, Reid IN, et al. Hashimoto’s encephalopathy: postmortem findings after fatal status epilepticus. Neurology 2003 Oct 28; 61(8): 1124–6

    Article  PubMed  Google Scholar 

  79. Josephs KA, Rubino FA, Dickson DW. Nonvasculitic autoimmune inflammatory meningoencephalitis. Neuropathology 2004 Jun; 24(2): 149–52

    Article  PubMed  Google Scholar 

  80. Mahad DJ, Staugaitis S, Ruggieri P, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. J Neurol Sci 2005 Jan 15; 228(1): 3–5

    Article  PubMed  Google Scholar 

  81. Mikaeloff Y, Caridade G, Husson B, et al. Acute disseminated encephalomyelitis cohort study: prognostic factors for relapse. Eur J Paediatr Neurol 2007; 11(2): 90–5

    Article  PubMed  Google Scholar 

  82. Rodien P, Madec AM, Ruf J, et al. Antibody-dependent cell-mediated cytotoxicity in autoimmune thyroid disease: relationship to antithyroperoxidase antibodies. J Clin Endocrinol Metab 1996 Jul; 81(7): 2595–600

    Article  PubMed  CAS  Google Scholar 

  83. Jacob S, Rajabally YA. Hashimoto’s encephalopathy: steroid resistance and response to intravenous immunoglobulins. J Neurol Neurosurg Psychiatry 2005 Mar; 76(3): 455–6

    Article  PubMed  CAS  Google Scholar 

  84. Sambrook PN. How to prevent steroid induced osteoporosis. Ann Rheum Dis 2005 Feb; 64(2): 176–8

    Article  PubMed  CAS  Google Scholar 

  85. Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003 Jun; 32(6): 370–7

    Article  PubMed  CAS  Google Scholar 

  86. Marshall GA, Doyle JJ. Long-term treatment of Hashimoto’s encephalopathy. J Neuropsychiatry Clin Neurosci 2006; 18(1): 14–20

    Article  PubMed  Google Scholar 

  87. Shaw PJ, Walls TJ, Newman PK, et al. Hashimoto’s encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers: report of 5 cases. Neurology 1991; 41(2 Pt 1): 228–33

    Article  PubMed  CAS  Google Scholar 

  88. Nagpal T, Pande S. Hashimoto’s encephalopathy: response to plasma exchange. Neurol India 2004 Jun; 52(2): 245–7

    PubMed  Google Scholar 

  89. Boers PM, Colebatch JG. Hashimoto’s encephalopathy responding to plasmapheresis [letter]. J Neurol Neurosurg Psychiatry 2001; 70(1): 132

    Article  PubMed  CAS  Google Scholar 

  90. Fatemi S, Bedri J, Nicoloff JT. Encephalopathy associated with Hashimoto’s thyroiditis: use of serum immunoglobulin G as a marker of disease activity. Thyroid 2003 Feb; 13(2): 227–8

    Article  PubMed  Google Scholar 

  91. Caselli RJ, Boeve BF, Scheithauer BW, et al. Nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM): a reversible form of encephalopathy. Neurology 1999 Oct 22; 53(7): 1579–81

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Neuropsychiatry Unit, The Royal Melbourne Hospital, Level 2, John Cade Building, Grattan Street, Parkville, Victoria, 3050, Australia

    Ramon Mocellin, Mark Walterfang & Dennis Velakoulis

  2. Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, Parkville, Victoria, Australia

    Ramon Mocellin, Mark Walterfang & Dennis Velakoulis

Authors
  1. Ramon Mocellin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Walterfang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dennis Velakoulis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ramon Mocellin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mocellin, R., Walterfang, M. & Velakoulis, D. Hashimoto’s Encephalopathy. CNS Drugs 21, 799–811 (2007). https://doi.org/10.2165/00023210-200721100-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200721100-00002

Keywords

Search

Navigation